Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives $8.50 Consensus Target Price from Brokerages

Aquestive Therapeutics, Inc. (NASDAQ:AQST) has earned an average recommendation of “Buy” from the seven analysts that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $8.50.

AQST has been the topic of a number of recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Friday, July 17th. Oppenheimer assumed coverage on shares of Aquestive Therapeutics in a report on Friday, April 24th. They set an “outperform” rating and a $8.00 target price for the company. Finally, Wall Street Zen cut Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday.

Aquestive Therapeutics Trading Up 0.9%

Shares of AQST stock opened at $4.29 on Thursday. Aquestive Therapeutics has a 12 month low of $2.93 and a 12 month high of $7.55. The stock has a market cap of $538.45 million, a PE ratio of -6.60 and a beta of 1.49. The company’s fifty day moving average price is $4.15 and its 200-day moving average price is $4.09.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.08). The firm had revenue of $13.82 million for the quarter, compared to analysts’ expectations of $11.42 million. On average, sell-side analysts forecast that Aquestive Therapeutics will post -0.45 earnings per share for the current fiscal year.

Insider Transactions at Aquestive Therapeutics

In other Aquestive Therapeutics news, Director Julie Krop sold 25,000 shares of Aquestive Therapeutics stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $5.02, for a total transaction of $125,500.00. Following the completion of the transaction, the director owned 25,000 shares in the company, valued at approximately $125,500. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.81% of the company’s stock.

Hedge Funds Weigh In On Aquestive Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of AQST. Victory Capital Management Inc. raised its position in shares of Aquestive Therapeutics by 17.0% in the 3rd quarter. Victory Capital Management Inc. now owns 12,794 shares of the company’s stock worth $72,000 after purchasing an additional 1,862 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Aquestive Therapeutics by 6.0% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,098 shares of the company’s stock valued at $156,000 after purchasing an additional 2,649 shares during the last quarter. Informed Momentum Co LLC increased its stake in Aquestive Therapeutics by 1.8% during the 4th quarter. Informed Momentum Co LLC now owns 155,053 shares of the company’s stock valued at $1,002,000 after purchasing an additional 2,721 shares in the last quarter. Sugar Maple Asset Management LLC increased its stake in Aquestive Therapeutics by 5.9% during the 1st quarter. Sugar Maple Asset Management LLC now owns 58,060 shares of the company’s stock valued at $241,000 after purchasing an additional 3,210 shares in the last quarter. Finally, Stifel Financial Corp raised its holdings in Aquestive Therapeutics by 0.9% in the fourth quarter. Stifel Financial Corp now owns 369,728 shares of the company’s stock worth $2,388,000 after buying an additional 3,300 shares during the last quarter. 32.45% of the stock is currently owned by institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.